On Thursday, March 9, Dr. A. Mark Fendrick, MD, Director of the Center for Value-Based Insurance Design (V-BID), presented at the NAM Roundtable on Genomics and Precision Health in Washington, DC (view event agenda here).

The meeting explored issues surrounding the return on investment of genomic medicine programs.  Issues included the integration and coordination of genomic information into health care and public health, including encompassing standards for genetic screening and testing, improving information technology for use in clinical decision-making, ensuring access while protecting privacy, and using genomic information to reduce health disparities.

Dr. Fendrick presented during Session IV, “Assessing the Return on Investment of Genomic Medicine.”  The objectives of this panel were to gather information on how return on investment of genomic medicine tests/services is assessed and acted upon, and to explore the economic considerations that underlie the decision to implement genomic medicine programs, from the perspective of payers, health economists, and integrated health care systems.

Click here or on the image below to view Dr. Fendrick’s presentation.

“Star Wars Science, Flintstone Delivery”

Precison Medicine Infographic   Precison Medicine One-Pager

Good Soldier Whiteboard Video   Good Soldier Issue Brief (NPC)   Specialty Pharma White Paper